Adult papillary meningioma
disease diseaseOn this page
Also known as papillary meningiomapapillary meningioma of adults
Summary
Adult papillary meningioma (MONDO:0004373) is a disease and 7 clinical trials. Top therapeutic interventions include bevacizumab, edotreotide gallium ga-68, and gadobenate dimeglumine. A subtype of rhabdoid meningioma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Clinical trials: 7
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | adult papillary meningioma |
| Mondo ID | MONDO:0004373 |
| DOID | DOID:7826 |
| NCIT | C8293 |
| UMLS | C0281334 |
| MedGen | 76256 |
| GARD | 0023966 |
| Is cancer (heuristic) | no |
Also known as: adult papillary meningioma · papillary meningioma · papillary meningioma of adults
Data availability: 4 cell lines.
Disease family
This is a subtype of rhabdoid meningioma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by body system or component › nervous system disorder › central nervous system disorder › central nervous system neoplasm › tumor of meninges › meningioma › rhabdoid meningioma › adult papillary meningioma
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 7.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 4 |
| PHASE2 | 2 |
| PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00492089 | PHASE2 | COMPLETED | Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer |
| NCT01125046 | PHASE2 | COMPLETED | Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas |
| NCT01119599 | PHASE1 | COMPLETED | RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma |
| NCT01234805 | Not specified | TERMINATED | Yoga Therapy in Treating Patients With Malignant Brain Tumors |
| NCT02194452 | Not specified | WITHDRAWN | Efficacy of 68Ga-DOTATOC Positron Emission Tomography (PET) CT in Children and Young Adults With Brain Tumors |
| NCT02967380 | Not specified | TERMINATED | Gadobutrol Versus Gadopentetate Dimeglumine or Gadobenate Dimeglumine Before DCE-MRI in Diagnosing Patients With Multiple Sclerosis, Grade II-IV Glioma, or Brain Metastases |
| NCT02973256 | Not specified | UNKNOWN | Oncological Care for Patients With Meningioma |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| BEVACIZUMAB | 4 | 2 |
| EDOTREOTIDE GALLIUM GA-68 | 4 | 1 |
| GADOBENATE DIMEGLUMINE | 4 | 1 |
| GADOBUTROL | 4 | 1 |
| GADOPENTETATE DIMEGLUMINE | 4 | 1 |